Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 16/20 | 1.00 |
| ▸ | PBK | Q96KB5 | 7/20 | 1.00 |
| ▸ | CCNK | O75909 | 1/20 | 0.79 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546962 | 1.00 | NEK1 (1.00) | NEK1PBKCCNKCDK12 | |
| SCHEMBL29653470 | 1.00 | NEK1 (1.00) | NEK1PBKCCNKCDK12 | |
| SCHEMBL2546969 | 1.00 | NEK1 (1.00) | NEK1PBKCCNKCDK12 | |
| Hydrochloric Acid SCHEMBL15092326 | 0.99 | NEK1 (0.98) | NEK1PBKCCNKCDK12 | |
| Hydrochloric Acid SCHEMBL15092325 | 0.99 | NEK1 (0.98) | NEK1PBKCCNKCDK12 | |
| SCHEMBL28817209 | 0.94 | NEK1 (0.89) | NEK1PBKCCNKCDK12 | |
| SCHEMBL28817207 | 0.94 | NEK1 (0.89) | NEK1PBKCCNKCDK12 | |
| Hydrochloric Acid SCHEMBL29784764 | 0.93 | NEK1 (0.88) | NEK1PBKCCNKCDK12 | |
| SCHEMBL15092424 | 0.92 | NEK1 (1.00) | NEK1PBKCCNKCDK12 | |
| SCHEMBL2559048 | 0.92 | NEK1 (1.00) | NEK1PBKCCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-118987016-A | Application of antisense oligonucleotide in preparing medicament for treating glioma | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-08-15 | — | — | US | claimed |
| WO-2024133845-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| WO-2024008833-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2024-01-11 | — | — | WO | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| US-20230060581-A1 | METHOD OF TREATING PANCREATIC CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2023-03-02 | — | — | US | claimed |
| US-20230042367-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-02-09 | — | — | US | claimed |
| EP-4103286-A1 | METHOD OF TREATING PANCREATIC CANCER | Cedars-Sinai Medical Center (US) | 2022-12-21 | — | — | EP | claimed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | claimed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | claimed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | claimed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | claimed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250339412-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | NUVALENT INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12404327-B2 | LILRB3-binding molecules and uses therefor | UNIVERSITY HEALTH NETWORK (CA) | 2025-09-02 | — | — | US | disclosed |
| EP-4582100-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250170133-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-12286476-B2 | FCMR-binding molecules and uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2025-04-29 | — | — | US | disclosed |
| WO-2025082484-A1 | TREATMENT OF PATIENT WITH NEGATIVE P53 GENE MUTATION, POSITIVE KRAS GENE MUTATION AND POSITIVE BRCA MUTATION | 深圳艾欣达伟医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| EP-4538708-A1 | METHOD FOR IMPROVING EXPERIMENTAL FLUX OF INTERACTION BETWEEN COMPOUNDS AND PROTEINS | Southern University of Science and Technology (CN) | 2025-04-16 | — | — | EP | disclosed |
| CN-119789868-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025072384-A1 | 5/6-5/6-BISARYL COMPOUNDS AS TAK1 INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025072117-A1 | HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS AND ISOTOPOLOGUES THEREOF | NUVALENT, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025072120-A1 | HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | disclosed |
| CN-119735682-A | BTLA binding (CD 272) antibodies for modulating immune responses and treating diseases | 库里亚知识产权控股有限责任公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250095772-A1 | METHOD FOR IMPROVING THROUGHPUT OF COMPOUND-PROTEIN INTERACTION EXPERIMENTS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-03-20 | — | — | US | disclosed |
| EP-4504189-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | Nuvalent, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4499101-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | Merck Sharp & Dohme LLC (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-114585416-B | BTLA binding (CD 272) antibodies for modulating immune responses and treating diseases | 莱克制药股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119212705-A | Methods of treating solid tumors using (19R) -5-chloro-3-ethyl-16-fluoro-10, 19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo [19.3.1.02,6.08,12.013,18] cyclopentadec-1 (24), 2 (6), 4,8,11,13,15,17,21 (25), 22-decen-22-amine | 纽威伦特公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| CN-118987016-A | Application of antisense oligonucleotide in preparing medicament for treating glioma | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118946359-A | Pharmaceutical combinations of amino-pyrrolopyrimidinone compounds and methods of use | 默沙东有限责任公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| WO-2024133845-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024097228-A1 | COMPOUNDS TARGETING CDK11 AND METHODS OF USING THE SAME | MELIORA THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240150462-A1 | LILRB1 AND LILRB2-BINDING MOLECULES AND USES THEREFOR | UNIV HEALTH NETWORK (CA) | 2024-05-09 | — | — | US | disclosed |
| WO-2024048541-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2024-03-07 | — | — | WO | disclosed |
| EP-4305068-A1 | LILRB1 AND LILRB2-BINDING MOLECULES AND USES THEREFOR | University Health Network (CA) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024008833-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2024-01-11 | — | — | WO | disclosed |
| CN-117321083-A | LILRB1 and LILRB2 binding molecules and uses thereof | 大学保健网 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023236909-A1 | METHOD FOR IMPROVING EXPERIMENTAL FLUX OF INTERACTION BETWEEN COMPOUNDS AND PROTEINS | 南方科技大学 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20230340123-A1 | BTLA-BINDING ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2023-10-26 | — | — | US | disclosed |
| WO-2023196910-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | NUVALENT, INC (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023192183-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| CN-116819086-A | Method for improving experimental flux of interaction between compound and protein | 南方科技大学 | 2023-09-29 | — | — | CN | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-11622965-B2 | Methods for treating lymphoid malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2023-04-11 | — | — | US | disclosed |
| US-20230076977-A1 | UTROPHIN UPREGULATION COMPOUNDS FOR DUCHENNE MUSCULAR DYSTROPHY THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230060581-A1 | METHOD OF TREATING PANCREATIC CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230042367-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230042367-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-02-09 | — | — | US | disclosed |
| EP-4103286-A1 | METHOD OF TREATING PANCREATIC CANCER | Cedars-Sinai Medical Center (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022187968-A1 | LILRB1 AND LILRB2-BINDING MOLECULES AND USES THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2022-09-15 | — | — | WO | disclosed |
| CN-114790209-A | Optimized combinations and their use for the treatment of cancer and autoimmune diseases | 浙江导明医药科技有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-108341774-B | Substituted quinolinone inhibitors | 首药控股(北京)股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-11384146-B2 | BTLA-binding antibodies for modulating immune response and treating disease | CURIA IP HOLDINGS, LLC (US) | 2022-07-12 | — | — | US | disclosed |
| US-11369620-B2 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2022-06-28 | — | — | US | disclosed |
| CN-109761902-B | 6-phenanthridinone derivative and preparation method and application thereof | 四川大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-114585416-A | BTLA binding (CD 272) antibodies for modulating immune responses and treating diseases | 莱克制药股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220153834-A1 | TSG-6 ANTIBODIES AND USES THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2022-05-19 | — | — | US | disclosed |
| US-20220089723-A1 | LILRB3-BINDING MOLECULES AND USES THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2022-03-24 | — | — | US | disclosed |
| US-20220089725-A1 | FCMR-Binding Molecules and Uses Thereof | UNIVERSITY HEALTH NETWORK (CA) | 2022-03-24 | — | — | US | disclosed |
| US-11246877-B2 | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3946622-A1 | BTLA-BINDING (CD272) ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE | Lakepharma, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3938389-A1 | TSG-6 ANTIBODIES AND USES THEREFOR | University Health Network (CA) | 2022-01-19 | — | — | EP | disclosed |
| EP-3924388-A1 | FCMR-BINDING MOLECULES AND USES THEREOF | University Health Network (CA) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021108927-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021108927-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2021-06-10 | — | — | WO | disclosed |
| US-20200323885-A1 | Pharmaceutical Compositions and Their Use for Treatment of Cancer and Autoimmune Diseases | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2020-10-15 | — | — | US | disclosed |
| US-20200325230-A1 | BTLA-BINDING ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2020-10-15 | — | — | US | disclosed |
| WO-2020205849-A1 | BTLA-BINDING (CD272) ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE | LAKEPHARMA, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020181376-A1 | TSG-6 ANTIBODIES AND USES THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020163962-A1 | FCMR-BINDING MOLECULES AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2020-08-20 | — | — | WO | disclosed |
| US-10596183-B2 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2020-03-24 | — | — | US | disclosed |
| US-20190269706-A1 | NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | THE UNIVERSITY OF CHICAGO | 2019-09-05 | — | — | US | disclosed |
| US-20190192541-A1 | Pharmaceutical Compositions and Their Use for Treatment of Cancer and Autoimmune Diseases | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2019-06-27 | — | — | US | disclosed |
| EP-3471735-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang Dtrm Biopharma Co. Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360853-A1 | Pharmaceutical Compositions and Their Use for Treatment of Cancer and Autoimmune Diseases | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-12-20 | — | — | US | disclosed |
| US-10098900-B2 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-10-16 | — | — | US | disclosed |
| WO-2017218844-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-12-21 | — | — | WO | disclosed |
| US-20170281810-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-10-05 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-9717745-B2 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-08-01 | — | — | US | disclosed |
| US-20160324878-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2016-11-10 | — | — | US | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | disclosed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269706-A1 | NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | CD274, PDCD1, PDCD1LG2 | NEK1 3730/4885PBK 71/4885CCNK 678/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | NEK1 1240/4885PBK 653/4885CCNK 55/4885 |
| US-20250170133-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | BTK, SYK, LCK | NEK1 1296/4885PBK 463/4885CCNK 1682/4885 |
| US-11246877-B2 | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof | CD274, PDCD1, PDCD1LG2 | NEK1 3730/4885PBK 71/4885CCNK 678/4885 |
| US-11622965-B2 | Methods for treating lymphoid malignancies | BTK, BCL6, BCL6B | NEK1 1179/4885PBK 16/4885CCNK 897/4885 |
| US-10596183-B2 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | BTK, BCL9, BCL9L | NEK1 1039/4885PBK 158/4885CCNK 651/4885 |
| US-10098900-B2 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | BTK, BCL9, BCL9L | NEK1 1039/4885PBK 158/4885CCNK 651/4885 |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | NEK1 62/4885PBK 10/4885CCNK 152/4885 |
| US-20190192541-A1 | Pharmaceutical Compositions and Their Use for Treatment of Cancer and Autoimmune Diseases | BTK, BCL9, BCL9L | NEK1 1039/4885PBK 158/4885CCNK 651/4885 |
| US-11369620-B2 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | BTK, BCL9, BCL9L | NEK1 1039/4885PBK 158/4885CCNK 651/4885 |
| US-20230076977-A1 | UTROPHIN UPREGULATION COMPOUNDS FOR DUCHENNE MUSCULAR DYSTROPHY THERAPY | UTRN, MTPN, MBNL1 | NEK1 3093/4885PBK 4852/4885CCNK 3013/4885 |
| US-20230042367-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION | CDKL1, CDK1, CDK17 | NEK1 177/4885PBK 3287/4885CCNK 43/4885 |
| US-20250339412-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | IL23R, IL17A, CA14 | NEK1 2988/4885PBK 977/4885CCNK 3986/4885 |
| US-20170281810-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | BTK, BCL9, BCL9L | NEK1 1039/4885PBK 158/4885CCNK 651/4885 |
| US-20200323885-A1 | Pharmaceutical Compositions and Their Use for Treatment of Cancer and Autoimmune Diseases | BTK, BCL9, BCL9L | NEK1 1039/4885PBK 158/4885CCNK 651/4885 |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | PTH1R, SELPLG, CALCR | NEK1 4142/4885PBK 2269/4885CCNK 2310/4885 |
| US-20180360853-A1 | Pharmaceutical Compositions and Their Use for Treatment of Cancer and Autoimmune Diseases | BTK, BCL9, BCL9L | NEK1 1039/4885PBK 158/4885CCNK 651/4885 |
| US-20160324878-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | BTK, BCL9, BCL9L | NEK1 1039/4885PBK 158/4885CCNK 651/4885 |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | PBDC1, SBK1, PLK2 | NEK1 62/4885PBK 10/4885CCNK 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.